StockData
Biodesix Inc logo

Biodesix Inc (BDSX) stock

BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$8.88−0.12 (-1.33%)

Close on Nov 17, 2026Market cap $93.69MP/E –Yield –

Biodesix operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Biodesix's operating income for the twelve months ending Jun 30, 2026 was -$20.61M. For fiscal 2025 it was -$27.87M. The highest annual figure on record is -$22.93M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.87M–
FY2024Dec 31, 2024-$34.50M–
FY2023Dec 31, 2023-$41.34M–
FY2022Dec 31, 2022-$50.59M–
FY2021Dec 31, 2021-$40.94M–
FY2020Dec 31, 2020-$22.93M–
FY2019Dec 31, 2019-$26.74M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.39M–
Q1 FY2026Mar 31, 2026-$6.20M–
Q4 FY2025Dec 31, 2025-$1.97M–
Q3 FY2025Sep 30, 2025-$7.05M–
Q2 FY2025Jun 30, 2025-$9.72M–
Q1 FY2025Mar 31, 2025-$9.14M–
Q4 FY2024Dec 31, 2024-$6.65M–
Q3 FY2024Sep 30, 2024-$8.59M–
Q2 FY2024Jun 30, 2024-$8.24M–
Q1 FY2024Mar 31, 2024-$11.02M–
Q4 FY2023Dec 31, 2023-$6.87M–
Q3 FY2023Sep 30, 2023-$7.17M–
Q2 FY2023Jun 30, 2023-$10.93M–
Q1 FY2023Mar 31, 2023-$16.37M–
Q4 FY2022Dec 31, 2022-$13.89M–
Q3 FY2022Sep 30, 2022-$10.61M–
Q2 FY2022Jun 30, 2022-$11.63M–
Q1 FY2022Mar 31, 2022-$14.46M–
Q4 FY2021Dec 31, 2021-$11.68M–
Q3 FY2021Sep 30, 2021-$13.09M–
Q2 FY2021Jun 30, 2021-$10.59M–
Q1 FY2021Mar 31, 2021-$5.58M–
Q4 FY2020Dec 31, 2020-$2.65M–
Q3 FY2020Sep 30, 2020-$6.24M–
Q2 FY2020Jun 30, 2020-$5.62M–
Q1 FY2020Mar 31, 2020-$8.42M–
Q4 FY2019Dec 31, 2019-$3.54M–
Q3 FY2019Sep 30, 2019-$9.03M–

More Biodesix figures

See a number that looks wrong?